Clinicopathologic Evaluation of Borderline Ovarian Tumours: A Tertiary Centre Experience

Authors : Sultan Deniz Altındağ, Seyran Yiğit, İrfan Öcal, Aylin Çallı, Serhat Şen
Pages : 52-57
View : 19 | Download : 19
Publication Date : 2025-04-30
Article Type : Research Paper
Abstract :Objective: Borderline ovarian tumours (BOTs) are rare tumours that are in the intermediate category of benign and malignant ovarian neoplasms. In this study, the clinicopathological features of the cases diagnosed with BOT in the pathology department are presented. Material and methods: The 139 patients were selected retrospectively. Haematoxylin&eosin slides were re-evaluated according to the 2020 World Health Organization classification. The data of the patients were obtained from the hospital archive. Results: The mean age was 44.8. Intraoperative consultation was performed on 114 patients and 86 of them (75.4%) were diagnosed with BOT. The most common histology was serous, followed by mucinous and seromucinous (54.8%, 32.5%, and 7.6%, respectively). Serous histology was observed in 16 of 18 bilateral BOT patients and mucinous histology was not seen. Mean tumour sizes were 10.4 cm in serous BOTs, 18.5 cm in mucinous BOTs and 12.4 cm in seromucinous BOTs. Mean CA-125 levels were 180.2 U/ml (N: 35 U/ml) in serous BOTs, 49.5 U/ml in mucinous BOTs and 35.4 U/ml in seromucinous BOTs. Mean CA-19.9 levels were 85.6 U/ml (N: 35 U/ml) in serous BOTs, 54.4 U/ml in mucinous BOTs and 93 U/ml in seromucinous BOTs. The recurrence rate was 10.9% (n=15), and no disease-related death was seen. Conclusion: Serous BOT is the most common subtype, and especially the vast majority of bilateral BOT has serous histology. Interestingly, the mean CA-19.9 level of seromucinous BOTs was higher than serous and mucinous BOTs. Since the recurrence was observed in very few patients, and no disease-related death was detected, the prognosis can be said to be excellent.
Keywords : Borderline ovarian tumour, Brenner tumour, Neoplasms, cystic, mucinous, and serous, Ovarian neoplasms, Recurrence

ORIGINAL ARTICLE URL